- Home
- MGRX vs CELZ Comparison
MGRX vs CELZ Comparison
Compare MGRX & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | CELZ |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.6M |
| IPO Year | 2023 | 2008 |
Fundamental Metrics
Financial Performance| Metric | MGRX | CELZ |
|---|---|---|
| Price | $0.20 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 378.6K | 91.3K |
| Earning Date | 11-24-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | 32.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $456,021.00 | $6,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.18 | $0.59 |
| 52 Week High | $2.28 | $4.72 |
Technical Indicators
Market Signals| Indicator | MGRX | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 39.16 |
| Support Level | N/A | $0.62 |
| Resistance Level | $0.48 | $0.93 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 22.50 | 27.39 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.